Gritstone bio Past Earnings Performance
Past criteria checks 0/6
Gritstone bio's earnings have been declining at an average annual rate of -11.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 10.8% per year.
Key information
-11.2%
Earnings growth rate
23.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 10.8% |
| Return on equity | -599.5% |
| Net Margin | -910.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gritstone bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 15 | -133 | 32 | 0 |
| 31 Mar 24 | 16 | -145 | 31 | 0 |
| 31 Dec 23 | 16 | -138 | 29 | 0 |
| 30 Sep 23 | 10 | -139 | 28 | 0 |
| 30 Jun 23 | 12 | -130 | 27 | 0 |
| 31 Mar 23 | 15 | -125 | 28 | 0 |
| 31 Dec 22 | 20 | -120 | 29 | 0 |
| 30 Sep 22 | 19 | -118 | 29 | 0 |
| 30 Jun 22 | 18 | -116 | 29 | 0 |
| 31 Mar 22 | 16 | -112 | 27 | 0 |
| 31 Dec 21 | 48 | -75 | 26 | 0 |
| 30 Sep 21 | 46 | -72 | 25 | 0 |
| 30 Jun 21 | 45 | -70 | 24 | 0 |
| 31 Mar 21 | 42 | -71 | 23 | 0 |
| 31 Dec 20 | 4 | -105 | 21 | 0 |
| 30 Sep 20 | 4 | -106 | 21 | 0 |
| 30 Jun 20 | 4 | -107 | 21 | 0 |
| 31 Mar 20 | 4 | -103 | 20 | 0 |
| 31 Dec 19 | 4 | -94 | 19 | 0 |
| 30 Sep 19 | 5 | -84 | 18 | 0 |
| 30 Jun 19 | 4 | -75 | 16 | 0 |
| 31 Mar 19 | 3 | -69 | 14 | 0 |
| 31 Dec 18 | 1 | -65 | 12 | 0 |
| 30 Sep 18 | 0 | -65 | 10 | 0 |
| 30 Jun 18 | 0 | -56 | 8 | 0 |
| 31 Mar 18 | 0 | -47 | 7 | 0 |
| 31 Dec 17 | 0 | -41 | 6 | 0 |
Quality Earnings: 2JQ is currently unprofitable.
Growing Profit Margin: 2JQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2JQ is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare 2JQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2JQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 2JQ has a negative Return on Equity (-599.54%), as it is currently unprofitable.